VIRPAX PHARMACEUTICALS, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 3.1 USD | +6.22% |
|
-15.76% | -3.16% |
Valuation
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|
| Capitalization 1 | 40.18 | 7.29 | 3.75 | 3.631 | - | - |
| Enterprise Value (EV) 1 | 40.18 | 7.29 | 3.75 | 3.631 | 3.631 | 3.631 |
| P/E ratio | - | -0.34 x | -0.25 x | -0.38 x | -0.38 x | -0.39 x |
| Yield | - | - | - | - | - | - |
| Capitalization / Revenue | - | - | - | - | - | - |
| EV / Revenue | - | - | - | - | - | - |
| EV / EBITDA | - | - | - | - | - | - |
| EV / FCF | - | - | - | - | - | - |
| FCF Yield | - | - | - | - | - | - |
| Price to Book | - | - | - | - | - | - |
| Nbr of stocks (in thousands) | 1,172 | 1,171 | 1,171 | 1,171 | - | - |
| Reference price 2 | 34.30 | 6.223 | 3.201 | 3.100 | 3.100 | 3.100 |
| Announcement Date | 3/31/22 | 3/22/23 | 3/26/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Net sales 1 | - | - | - | - | - | - | - |
| EBITDA | - | - | - | - | - | - | - |
| EBIT 1 | - | -12.03 | -21.85 | -15.69 | -17.43 | -22.54 | -25.66 |
| Operating Margin | - | - | - | - | - | - | - |
| Earnings before Tax (EBT) 1 | - | - | -21.65 | -15.19 | -17.43 | -22.54 | -25.66 |
| Net income 1 | -4.34 | - | -21.65 | -15.19 | -17.43 | -22.54 | -25.66 |
| Net margin | - | - | - | - | - | - | - |
| EPS 2 | -14.00 | - | -18.50 | -12.97 | -8.200 | -8.200 | -7.900 |
| Free Cash Flow | - | - | - | - | - | - | - |
| FCF margin | - | - | - | - | - | - | - |
| FCF Conversion (EBITDA) | - | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - | - |
| Announcement Date | 3/31/21 | 3/31/22 | 3/22/23 | 3/26/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 |
|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | - | - | - | - | - | - | - | - | - |
| EBITDA | - | - | - | - | - | - | - | - | - |
| EBIT 1 | -4.122 | - | -5.904 | -7.715 | -3.102 | -1.651 | -3.239 | - | -4.684 |
| Operating Margin | - | - | - | - | - | - | - | - | - |
| Earnings before Tax (EBT) 1 | - | - | -5.885 | -7.642 | -2.987 | -1.521 | -3.113 | - | -4.562 |
| Net income 1 | - | -5.137 | -5.885 | -7.642 | -2.987 | -1.521 | -3.113 | - | -4.562 |
| Net margin | - | - | - | - | - | - | - | - | - |
| EPS 2 | - | -4.400 | -5.000 | -6.500 | -2.600 | -1.300 | -2.700 | - | -12.06 |
| Dividend per Share | - | - | - | - | - | - | - | - | - |
| Announcement Date | 3/31/22 | 5/16/22 | 8/15/22 | 11/9/22 | 3/22/23 | 5/12/23 | 8/14/23 | 12/26/23 | 3/26/24 |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Net Debt | - | - | - | - | - | - | - |
| Net Cash position | - | - | - | - | - | - | - |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - | - |
| Free Cash Flow | - | - | - | - | - | - | - |
| ROE (net income / shareholders' equity) | - | - | - | - | - | - | - |
| ROA (Net income/ Total Assets) | - | - | - | - | - | - | - |
| Assets 1 | - | - | - | - | - | - | - |
| Book Value Per Share | - | - | - | - | - | - | - |
| Cash Flow per Share | - | - | - | - | - | - | - |
| Capex | - | - | - | - | - | - | - |
| Capex / Sales | - | - | - | - | - | - | - |
| Announcement Date | 3/31/21 | 3/31/22 | 3/22/23 | 3/26/24 | - | - | - |
1USD in Million
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
1
Last Close Price
3.1
USD
Average target price
20
USD
Spread / Average Target
+545.16%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -3.16% | 3.63M | |
| +1.51% | 42.75B | |
| +49.22% | 41.61B | |
| +8.57% | 41.34B | |
| -12.36% | 26.59B | |
| +8.92% | 25.49B | |
| -25.13% | 18.12B | |
| +29.17% | 12.24B | |
| -3.12% | 11.76B | |
| +6.35% | 11B |
- Stock Market
- Equities
- VRPX Stock
- Financials Virpax Pharmaceuticals, Inc.
